Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Conditions

Hypertension 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, Follicular 1Heart Failure 1Cardiovascular Diseases 1Cardiotoxicity 1

Interventions

Echocardiography 4sacubitril and valsartan sodium hydrate drug combination 3Standard of Care 3Nutrition Assessment 3Exercise 3Electrocardiography 3Carvedilol 3dapagliflozin 2Surveys and Questionnaires 2Spironolactone 2Rituximab 2Lenalidomide 2Ivabradine 2Control Groups 2Blood Specimen Collection 2Atorvastatin 2Adrenergic beta-Antagonists 2ziprasidone 1pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Zolpidem 1Watchful Waiting 1Warfarin 1Vincristine 1Vecuronium Bromide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × Angiotensin-Converting Enzyme Inhibitors × Clear all
NCT02818517 2022-02-02

Evaluation and Management of Cardio Toxicity in Oncologic Patients

Tel-Aviv Sourasky Medical Center

Recruiting
1,000 enrolled

Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡